Home
About
Overview
Sharing Data
ORCID
Help
History (5)
Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation-Rationale and design of the ENVISAGE-TAVI AF trial.
Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.
Jacobs, Christina
Multiple Health Risk Behaviors in Young Adult Smokers: Stages of Change and Stability over Time.
Top-down Mass Spectrometry Analysis of Human Serum Autoantibody Antigen-Binding Fragments.
See All 5 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.
Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR. N Engl J Med. 2021 12 02; 385(23):2150-2160.
View in:
PubMed
subject areas
4-Hydroxycoumarins
Aged
Aged, 80 and over
Anticoagulants
Atrial Fibrillation
Factor Xa Inhibitors
Female
Gastrointestinal Hemorrhage
Humans
Intention to Treat Analysis
Kaplan-Meier Estimate
Male
Mortality
Phenindione
Postoperative Complications
Pyridines
Thiazoles
Thromboembolism
Transcatheter Aortic Valve Replacement
Vitamin K
authors with profiles
Usman Baber